$IQEPF: MACOM's £45M Buy Tells You What the Market Missed
MACOM paid 9.6x its own sales multiple to lock in epiwafer supply it cannot source elsewhere, and the sell-side called the resulting price move expensive
Position disclosure: I am long IQEPF. This is my largest position at 35.1% of the portfolio. I entered near cycle lows at under 1x revenue. I reclassified IQEPF off my avoid list on 2026-04-18. This write-up reflects a position I already hold. Read accordingly.
MACOM Technology Solutions wrote a £30M equity check into IQE on April 26, 2026. Then it wrote a £15M zero-coupon convertible loan note. Then it signed long-term strategic supply agreements covering GaAs, InP, and GaN epitaxial services. Then it took two board seats.
That is not a financial investment. That is a strategic acquisition of supply-chain control dressed in minority-stake clothing.
The market gave IQE a 25-30% pop and then a sell-side downgrade citing "valuation run ahead of fundamentals." One analyst looked at the price action and called it expensive. The right frame is different. MACOM, a company trading at roughly 9.6x EV/Sales on its own revenue base, just paid to lock in IQE's output at a time when Western compound-semiconductor epiwafer capacity is the single most constrained input in the AI photonics supply chain. MACOM's CEO Stephen Daly said IQE is "an important supplier" and the transaction "will strengthen our supply chain resilience." That is not the language of a financial buyer. That is the language of a company that cannot afford to lose its epiwafer source.
Part 1 published a four-scenario valuation tree: bear $0.18, base $0.62, bull $1.55, moonshot $3.10, probability-weighted expected value approximately $0.85. Those numbers were correct on April 20, 2026. The scenarios remain valid as floors. What has changed is the probability distribution sitting on top of them. The MACOM deal, the Quintessent partnership, the Lumentum extension, the FY2025 EBITDA positive print, the Q1 2026 order book strength, and the defense funding acceleration have all shifted probability mass toward the right tail.
This piece does not repeat Part 1. It extends it. The new evidence is the thesis.
Let's go.
MACOM Wrote the Check That Ended the Existential Risk
The strategic review that began in November 2024 is over. Lazard, which IQE appointed as financial adviser, ran a process that included Taiwan divestment talks and approaches from potential whole-company buyers. On April 26, 2026, that process concluded. Not with a sale. With a recapitalization led by a strategic partner who needs IQE's output more than it needs the equity upside.
The structure of the £81M raise matters more than the headline number.
MACOM subscribed for 151,515,151 new ordinary shares at 19.8 pence per share, representing approximately £30M and roughly 11.5% of the enlarged voting rights. Simultaneously, MACOM provided a £15M zero-coupon convertible loan note with a 60-month term. Existing CLN holders, led by Lombard Odier, reinvested their March 2025 CLN positions into 115,011,962 new shares at the same 19.8p price, converting approximately £22.8M of debt into equity. The balance of the £81M total came from a placing and retail offer, with the retail tranche subject to shareholder approval at the General Meeting convened for May 15, 2026.
Use of proceeds: repay the HSBC revolving credit facility, redeem the March 2025 CLNs, and repair the balance sheet. The HSBC RCF was a $35M facility that required a covenant waiver on the Q4 2025 EBITDA test. That waiver is now being replaced with cash. The March 2025 CLNs, issued at £18M with a 15p conversion price and roughly 12-month maturity, are being redeemed. Net debt at H1 2025 was £23.5M. Post-transaction, IQE enters FY2026 with a materially cleaner balance sheet and no near-term covenant risk.
The Long-Term Strategic Supply Agreements signed at completion cover epitaxial services across multiple technologies. The RNS language is deliberately broad: GaAs, InP, GaN. That covers MACOM's entire compound-semiconductor product roadmap. MACOM's revenue base spans 100G to 800G datacenter interconnect, coherent optics, GaN RF for radar and defense, and 5G/6G base-station power amplifiers. Every one of those product lines needs epiwafer inputs that IQE grows.
Chart 1: IQE £81M raise by component. The MACOM equity and CLN together represent £45M of the £81M total. Lombard Odier's reinvestment converts existing debt to equity. The retail tranche closes the gap. Source: IQE RNS April 26, 2026.
The MACOM deal eliminates the three risks that were suppressing the multiple: covenant breach probability, CLN maturity cliff, and strategic-review uncertainty. All three are gone. The market priced in a 25-30% move. The correct re-rate is larger, because the market is still treating this as a distressed-industrial recovery rather than a strategic-partner validation of IQE's position in the AI photonics supply chain.
Semiecosystem put it plainly: "IQE: No Longer Up For Sale." That is the right frame. IQE is now a going concern with an anchor strategic partner, two board seats occupied by MACOM nominees, and multi-year supply agreements that create revenue floor visibility. The existential risk is gone. The market has not fully priced what that means for the multiple.
The Dilution Math and Why It Does Not Break the Thesis
The 19.8p issuance price is below the current trading price. That is dilutive. Paid readers deserve the honest math.
IQE had approximately 979M shares outstanding before the transaction. The MACOM equity tranche adds 151.5M shares. The Lombard Odier reinvestment adds 115M shares. The placing and retail offer adds additional shares to reach the £81M total. At 19.8p per share, the retail tranche of approximately £13.2M implies roughly 66.7M additional shares. Total new shares issued: approximately 333M, bringing the enlarged share count to approximately 1.31B shares. That matches the live quote data showing 1.31B shares outstanding as of May 5, 2026.
Dilution from the pre-transaction base: approximately 34%. That is real. It is also already in the price. The stock is trading at $0.60 as of May 5, 2026, which reflects the post-dilution share count. The Part 1 scenario tree used a pre-dilution share count. The implied prices in Part 1 need to be read against the enlarged share count. The bear floor of $0.18 and the base of $0.62 remain valid because the balance-sheet repair that the dilution funds is what makes those scenarios achievable rather than aspirational.
The key point: the dilution bought the company out of default risk. That is a good trade. A company that might have breached its HSBC covenant and faced a liquidity squeeze is now a company with a clean balance sheet, a strategic anchor investor, and multi-year supply agreements. The dilution is the price of survival and the price of the MACOM relationship. Both are worth paying.
Short interest data confirms the positioning uncertainty. IQEPF short interest dropped 85.2% in one reporting period, then surged 180.5% in the next. That is not a directional signal. That is a market that does not know what to do with a company that just went from distressed to strategically anchored in a single announcement. The confusion is the opportunity.
The Gross Margin Recovery Is the Operating Story
IQE's trailing gross margin is approximately 0% on a TTM basis. That is the number that makes the stock look broken. It is also the number that makes the recovery so powerful when it comes.
The gross margin collapsed for a specific reason: capacity underutilization. IQE's MOCVD reactors at Newport (Wales), Cardiff, Massachusetts, and Taiwan are fixed-cost machines. When revenue dropped from £118M in FY2024 to £97M in FY2025, the fixed costs did not drop with it. The result was negative operating on the way down. The same mechanism runs in reverse on the way up.
Newport is IQE's center of excellence for 6-inch GaAs VCSEL production. The site has at least 10 fully qualified MOCVD reactors. At H1 2025 revenue of £45.3M annualized, those reactors were running well below capacity. The H2 2025 recovery, driven by AI photonics demand and defense funding releases, began to absorb that slack. The January 2026 trading update confirmed FY2025 revenue at the top of the £90-100M guidance range and EBITDA at least £2M, the top of the -£5M to +£2M range. That EBITDA positive print at £97M revenue is the operating proof point.
The math on the recovery path is straightforward. IQE's cost structure at £118M revenue in FY2024 produced adjusted EBITDA of £8.1M, a 7% margin. At £97M revenue in FY2025, EBITDA was approximately £2M, a 2% margin. The revenue drop of £21M produced an EBITDA drop of approximately £6M. That implies a contribution margin on incremental revenue of roughly 29%. As revenue recovers toward and through the FY2024 level, each incremental pound of revenue should produce approximately 29 pence of EBITDA.
At £130M revenue (base case FY2027), that implies EBITDA of approximately £19M, a 15% margin. At £160M revenue (bull case FY2028), EBITDA approaches £28M, a 17-18% margin. At £200M revenue (asymmetric bull FY2029-2030), EBITDA reaches £40M+, a 20%+ margin. That is peer-level profitability. That is when the multiple re-rates from distressed-industrial to compound-semi foundry.
Chart 2: IQE revenue and EBITDA margin recovery. FY2024-FY2025 are reported actuals. FY2026 onward is Shawarma Capital base and bull case projection. The operating curve is steep because fixed costs are already absorbed at £97M. Source: IQE RNS, Shawarma Capital model.
The Newport site is the key variable. Six-inch GaAs VCSEL production for AI photonics and consumer sensing is the highest-margin product IQE grows. As photonics revenue grows as a share of the mix, gross margins recover faster than the blended contribution margin implies. The Lumentum multi-year extension signed December 8, 2025 locks in VCSEL epiwafer demand through the next consumer sensing cycle. The Quintessent partnership adds InP quantum dot laser demand on top of that. Both are Newport-eligible products.
The gross margin recovery is not a hope. It is a math problem with a known solution: more revenue through fixed-cost infrastructure. The MACOM LTSAs provide the demand floor. The photonics super-cycle provides the upside.
The Photonics Revenue Build: Bottom-Up by Customer and Product
The photonics segment is where the re-rate lives. In FY2024, photonics revenue was £49.9M, down 16% year-over-year. In H1 2025, photonics held flat at £26.6M as InP datacom strength offset defense IR delays. The Q1 2026 order book showed "higher than forecast photonics demand" linked specifically to AI and data-center markets.
Here is the bottom-up build by customer and product line.
Lumentum. The multi-year strategic supply agreement extended December 8, 2025 covers VCSEL epiwafers and advanced sensing technologies. Applications include consumer 3D sensing (the iPhone FaceID supply chain), automotive LiDAR, and in-cabin sensing. Jutta Meier's quote from the extension announcement: "Together we have achieved significant innovation in sensing technologies, from development through to mass production. We are excited to build on our success moving forward, as we expand advanced sensing into a new generation of consumer and automotive products." Lumentum is one of the two largest VCSEL module manufacturers globally. IQE is its qualified epiwafer foundry. The extension covers multiple product generations. Revenue contribution from the Lumentum relationship is not disclosed at the line-item level, but the photonics segment at £49.9M in FY2024 was substantially driven by VCSEL demand. The Lumentum extension sustains that floor through the next iPhone and Vision Pro cycles.
Apple / Vision Pro. IQE's Apple exposure runs through the Lumentum module path. IQE grows the VCSEL epiwafer. Lumentum packages it into a module. Apple integrates the module into FaceID and depth-sensing systems. The Vision Pro 2 ramp is not publicly confirmed at the IQE-Apple direct contract level, but the Lumentum extension explicitly covers "consumer applications" including 3D sensing. The in-housing risk is real but has not materialized. Apple's vertical integration strategy has consistently stopped at the module level for compound-semiconductor components where the process complexity is too high to replicate internally at scale. VCSEL epiwafer growth on GaAs is a 30-year accumulated process knowledge base. IQE has been doing it since the 1990s. The probability that Apple replicates that internally within the next three years is low. The probability that Apple continues to consume IQE-grown epiwafers through Lumentum is high.
Quintessent / Co-Packaged Optics. The January 24, 2025 partnership with Quintessent is the most forward-looking photonics catalyst in IQE's portfolio. Quintessent is building the world's first large-scale quantum dot laser and semiconductor optical amplifier epiwafer supply chain, targeting AI optical interconnects for co-packaged optics. The initial purchase order was approximately $0.5M for 2025 production deliveries. The technology migrates from 4-inch InP to 6-inch GaAs quantum-dot epiwafers, enabling production of hundreds of millions of edge-emitting lasers per year with improved reliability, temperature tolerance, and efficiency relative to conventional InP lasers. The research lineage runs through UC Santa Barbara professor John Bowers, a decade-plus collaboration. IQE is the named Western foundry for this supply chain. There is no other qualified Western source for quantum dot laser epiwafers at scale. The CPO market is being driven by Nvidia's Rubin photonics roadmap, Broadcom's Tomahawk-6 switch at 102.4 Tbps, Marvell's Teralynx, and Cisco Silicon One. IQE is not named in individual contracts with those hyperscalers. But IQE is the upstream epiwafer source for the technology that feeds them. The $0.5M 2025 purchase order is a seed. The CPO market is a multi-billion-dollar opportunity by 2028-2030.
MACOM / AI Datacenter Interconnect. The LTSAs signed with MACOM cover InP and GaAs epiwafers for MACOM's 100G to 800G datacenter interconnect and coherent optics product lines. MACOM's own revenue base in this segment is growing. IQE is now the locked-in epiwafer source. The Nvidia connection flagged by Proactive Financial News is real: MACOM supplies components into Nvidia's datacenter photonics ecosystem. IQE grows the epiwafers that MACOM processes into those components. The supply chain runs IQE to MACOM to Nvidia's datacenter customers.
Chart 3: IQE photonics revenue build by customer and product, FY2025 to FY2030. The MACOM AI datacenter line and the Quintessent CPO line are the growth drivers. Lumentum VCSEL is the stable floor. Defense IR is the underappreciated kicker. Source: IQE RNS, Shawarma Capital model.
The photonics segment at £50M in FY2024 was the low point of a cycle. The MACOM LTSAs, the Quintessent CPO ramp, and the Lumentum extension together create a credible path to £170M+ in photonics revenue by FY2030. That alone, at a 3x EV/Sales multiple, implies an enterprise value larger than IQE's entire current market cap.
Defense, GaN Power, and the Revenue Lines the Market Is Not Modeling
The defense and GaN power segments are the two most underappreciated revenue lines in IQE's portfolio. Neither is in the photonics narrative. Both are growing.
Defense and mmWave GaN. IQE's North Carolina facility was qualified by Raytheon for IR sensing in January 2024, a 15-year relationship. In 2026, IQE received $5.8M in IR purchase orders from two long-standing defense IR customers. The H2 2025 trading update cited "faster than expected funding releases" on US military and defense programs as a driver of the H2 recovery. The AFRL published a paper in 2015 documenting IQE's 100mm GaN-on-SiC epiwafers achieving record power density in Ka-band (40 GHz) MMICs. Ka-band is the frequency range for radar, electronic warfare, and secure satellite communications. That paper is a decade old. The technology has advanced. The qualification remains. IQE's GaN-on-SiC epiwafer is a qualified Western source for defense radar and EW applications. There is no Chinese substitute that passes Western export-control requirements. The defense revenue line is not large today. It is growing, it is export-controlled, and it carries higher margins than the wireless segment.
GaN Power for AI Datacenters. The AI datacenter power conversion opportunity is the least-discussed IQE catalyst. Nvidia's 800V HVDC architecture requires high-efficiency power conversion at every rack. Navitas Semiconductor's 10kW 800V-to-50V power bricks run at 98.5% efficiency using GaN. Efficient Power Conversion's eGaN FETs handle 48V-to-6V LLC modules at approximately 97% efficiency and approximately 1,700 W per cubic inch. Infineon is collaborating with Nvidia on the 800V architecture. IQE's GaN roadmap includes 650V E/D-mode GaN, vertical high-voltage GaN-on-GaN, and GaN-on-sapphire for EV and datacenter power management. IQE is in joint development with X-FAB for automotive power GaN, with sampling underway with leading automotive-power customers. Government-funded programs for greater than 1,000V vertical GaN are active. The datacenter power GaN market is in early innings. IQE is positioned as a qualified Western epiwafer source for the companies building the power conversion stack. The revenue is not material today. It will be by FY2028.
5G GaN RF. The wireless segment collapsed in H1 2025, down 52% year-over-year to £18.6M, driven by handset destocking and tariff uncertainty. The Q1 2026 order book showed "increased sales tied to new handset introductions" benefiting Taiwan operations. The wireless segment is recovering. IQE's GaAs pHEMT and GaN epiwafers feed the power amplifier supply chain for high-band 5G smartphones. Qorvo, Skyworks, and Broadcom are the module manufacturers. IQE is the upstream epiwafer source. The wireless segment at £67.3M in FY2024 was the largest revenue line. It will recover toward that level as handset demand normalizes.
Chart 4: IQE revenue by segment. Photonics overtakes wireless as the dominant segment by FY2027 in the base case. Defense and power GaN is the emerging third leg. Source: IQE RNS, Shawarma Capital model.
The three-segment structure matters for the multiple. A company with 65% photonics revenue, 25% wireless, and 10% defense/power GaN deserves a different multiple than a company with 60% wireless and 40% photonics. The mix shift is happening. The market is not pricing it.
The Peer Multiple Gap Is the Re-Rate Mechanism
IQE trades at approximately 6.7x EV/Revenue on a trailing basis as of May 5, 2026. That looks expensive until you understand what is in the denominator: a trough revenue year with negative gross margins. On a forward basis, using the FY2026 base case of £115M revenue, the EV/Revenue multiple is approximately 5.7x. On the FY2027 base case of £130M, it is approximately 5x. Those numbers are still above the peer group on a trailing basis, but the peer group is not the right comparison set.
The right comparison set is photonics and compound-semiconductor foundries at mid-cycle.
MACOM Technology Solutions, IQE's new strategic partner, trades at approximately 9.6x EV/Sales on its own revenue base. MACOM just paid to lock in IQE's output. If MACOM is worth 9.6x sales as a compound-semiconductor component manufacturer, what is IQE worth as the upstream epiwafer foundry that MACOM cannot operate without? Coherent, which manufactures compound-semiconductor components for datacenter optics, trades at approximately 3.35x EV/Sales. Navitas Semiconductor, a GaN power device company, trades at approximately 30.8x EV/Sales. Wolfspeed, post-Chapter 11, has distorted multiples due to the debt restructuring.
IQE at 2x EV/Sales on FY2027 revenue of £130M implies an enterprise value of £260M, or approximately $330M. Against 1.31B shares outstanding, that implies a share price of approximately $0.25. That is the bear case re-rate, not the base case. IQE at 3x EV/Sales on FY2027 revenue implies an enterprise value of £390M, or approximately $495M. Share price approximately $0.38. Still below current trading. The current price is pricing in a recovery to 5x+ EV/Sales on FY2027 revenue, which is achievable if the photonics mix shift materializes and the MACOM LTSAs provide volume visibility.
The UK AIM listing is a structural discount. IQE's peers trade on Nasdaq. The AIM market applies a liquidity discount and an analyst coverage discount relative to US-listed compound-semiconductor names. Quantifying the AIM discount precisely is difficult, but the observable fact is that MACOM at 9.6x EV/Sales and Coherent at 3.35x EV/Sales are US-listed. IQE at sub-1x trailing EV/Sales (pre-recovery) is AIM-listed. A US listing or a dual listing would close a meaningful portion of that gap. It is not a near-term catalyst. It is a structural optionality that exists.
Chart 5: Peer EV/Sales multiples. IQE's trailing multiple looks elevated because the denominator is trough revenue. On FY2027 base case revenue, IQE trades at 3.5-5x EV/Sales, a discount to MACOM and Coherent. Source: Operator research, Shawarma Capital model.
The re-rate mechanism is simple. As revenue recovers and gross margins turn positive, the trailing multiple compresses. As the photonics mix shift becomes visible in reported results, the peer comparison set shifts from distressed-industrial to compound-semi foundry. The MACOM strategic partnership provides the narrative anchor for that re-rating. The May 15, 2026 General Meeting approval is the first gate.
The Updated Scenario Tree: Probability Mass Has Moved
Part 1 published four scenarios. Those scenarios remain valid as floors. The probability weighting has changed. Here is the updated framework.
Bear case. 10% probability (down from 20%). Revenue stalls at £90-95M. Gross margins recover to only 5%. The MACOM LTSAs provide a floor but volume ramps slowly. The photonics super-cycle takes longer than expected. The May 15 General Meeting fails to approve the retail tranche (low probability but non-zero). Net debt remains elevated. Multiple stays at 1.5x EV/Sales. Implied share price: $0.18. The bear probability has dropped from 20% to 10% because the MACOM deal eliminates the covenant breach and liquidity squeeze scenarios that were the primary bear drivers.
Base case. 35% probability (down from 45%). Revenue recovers to £130M by FY2027. Gross margins reach 15%. MACOM LTSAs provide volume visibility. Photonics grows to 60% of revenue mix. Multiple expands to 3x EV/Sales as the recovery becomes visible in reported results. Implied share price: $1.00-1.50. The base probability has dropped from 45% to 35% because probability mass has shifted toward the bull scenarios given the new evidence.
Bull case. 35% probability (up from 25%). Revenue reaches £160M by FY2028. Gross margins reach 18-20%. The Quintessent CPO ramp contributes meaningfully from FY2027. Defense and power GaN become visible revenue lines. MACOM deepens the relationship. Multiple expands to 4-5x EV/Sales as the photonics foundry narrative takes hold. Implied share price: $2.50-4.00. Part 1's $1.55 bull is the floor of this range, not the ceiling.
Asymmetric Bull. 15% probability (new tier). Revenue reaches £200-250M by FY2029-2030. The CPO market inflects. GaN power for AI datacenters becomes a material revenue line. IQE's Newport site runs at full utilization on 6-inch GaAs VCSEL and quantum dot laser epiwafers. Gross margins reach 22-25%. Multiple expands to 5-7x EV/Sales as IQE is reclassified from AIM-listed distressed industrial to Western compound-semi foundry monopoly. Implied share price: $4.00-7.40. This is the operator's genuine view of the realistic bull case, not the moonshot.
Aggressive Moonshot. 5% probability (refined from Part 1's 10%). Strategic acquirer. MACOM's 11.5% stake and two board seats are the first step in a longer process. A full acquisition at 8-10x EV/Sales on £200M+ revenue implies a takeout price of £1.6B to £2B, or approximately $8-10 per IQEPF share. The China-restriction era makes Western compound-semiconductor foundry capacity a strategic asset. The UK government's compound-semiconductor industrial policy makes a forced sale to a non-Western buyer politically impossible. The plausible acquirers are MACOM itself, a US defense prime (Raytheon, L3Harris), or a European semiconductor group (Infineon, STMicroelectronics). The moonshot probability has dropped from 10% to 5% not because the scenario is less likely in absolute terms, but because the asymmetric bull scenario now captures much of what was previously moonshot territory.
Probability-weighted expected value:
0.10 x $0.18 + 0.35 x $1.25 + 0.35 x $3.25 + 0.15 x $5.70 + 0.05 x $9.00
= $0.018 + $0.4375 + $1.1375 + $0.855 + $0.45
= $2.90 probability-weighted expected value
Against the current price of $0.60, that is a 4.8x expected return. The math is the math.
Chart 6: Updated scenario valuation matrix. Probability mass has shifted from bear and base toward bull and asymmetric bull. The probability-weighted expected value is $2.90 against a current price of $0.60. Source: Shawarma Capital model.
Base-case 3-year IRR from $0.60 to $1.25: approximately 28% annualized. Bull-case 3-year IRR from $0.60 to $3.25: approximately 76% annualized. Asymmetric bull 4-year IRR from $0.60 to $5.70: approximately 75% annualized.
The Counter-Thesis: Every Bear Argument, Addressed Directly
Paid readers deserve the honest engagement. Here are the five strongest bear arguments and exactly why each fails to break the thesis.
Bear argument 1: Apple in-housing kills the VCSEL revenue line. Apple has been vertically integrating semiconductor components for 15 years. It designs its own application processors, neural engines, and modems. The argument is that Apple will eventually grow its own VCSEL epiwafers. The counter: Apple has never grown its own compound-semiconductor epiwafers. The process requires MOCVD reactors, III-V materials expertise, and decades of recipe development. Apple's vertical integration stops at the module level for compound-semiconductor components. The Lumentum multi-year extension signed December 8, 2025 covers multiple product generations. If Apple were planning to in-house VCSEL epiwafer production, Lumentum would not have extended its supply agreement with IQE. The extension is the evidence that the in-housing risk has not materialized and is not imminent.
Bear argument 2: Chinese entrants commoditize epiwafer production. China has been building compound-semiconductor capacity for a decade. The argument is that Chinese foundries will undercut IQE on price and take market share. The counter: Western defense and government customers require Western-qualified epiwafer sources. Export-control regulations prevent Chinese epiwafers from entering the US defense supply chain. IQE's Raytheon qualification, its North Carolina facility, and its UK government-funded GaN programs are all export-controlled assets. The MACOM LTSAs explicitly lock in IQE as a Western source. The China-restriction era makes IQE's Western qualification more valuable, not less. For commercial photonics, Chinese competition is real. For defense and export-controlled applications, it is not a factor.
Bear argument 3: Gross margins never recover because the cost structure is too fixed. The argument is that IQE's MOCVD reactors are expensive to run and the fixed-cost base is too high to generate meaningful margins at achievable revenue levels. The counter: IQE generated 7% adjusted EBITDA margins at £118M revenue in FY2024. The cost structure at that revenue level was already absorbing the fixed costs. The margin collapse at £97M revenue was a function of the revenue drop, not a structural change in the cost base. The operating math at 29% contribution margin on incremental revenue above £97M is derived from the actual FY2024 and FY2025 reported numbers. It is not an assumption. It is arithmetic.
Bear argument 4: Dilution from the 19.8p issuance is too severe. The argument is that issuing approximately 333M new shares at 19.8p permanently impairs the per-share value. The counter: the dilution is already in the price. The current share count of 1.31B shares is the post-dilution count. The $0.60 price reflects the enlarged share count. The dilution bought the company out of default risk and funded the MACOM strategic relationship. A company with 979M shares and a covenant breach risk is worth less than a company with 1.31B shares and a clean balance sheet plus a strategic anchor investor. The math favors the dilution.
Bear argument 5: The photonics super-cycle stalls and CPO takes longer than expected. The argument is that co-packaged optics adoption is slower than the market expects and IQE's Quintessent revenue ramp is pushed out. The counter: the Quintessent partnership is not the only photonics driver. The Lumentum VCSEL extension, the MACOM InP datacenter interconnect LTSAs, and the defense IR purchase orders are all independent revenue streams. If CPO takes until FY2029 instead of FY2027, the base case is delayed, not broken. The asymmetric bull scenario absorbs a two-year CPO delay and still implies a 5x+ return from current prices.
Chart 7: Risk matrix. The highest-probability risk is CPO cycle delay at 30%, but its severity is medium because independent revenue floors exist. The highest-severity risks (Apple in-housing, gross margin impairment) have low probability given current evidence. Source: Shawarma Capital model.
None of the bear arguments break the thesis. Each has a specific counter grounded in reported facts. The thesis survives all five.
Customer Qualification Status and the Revenue Concentration Question
Customer concentration is a real risk. IQE does not disclose individual customer revenue percentages. The top-5 customer concentration is not publicly stated. What is known: the wireless segment at £67.3M in FY2024 was driven by GaAs pHEMT and GaN epiwafers for smartphone power amplifiers. The photonics segment at £49.9M was driven by VCSEL and InP epiwafers for consumer sensing and datacenter optics. Both segments have concentrated customer bases.
The MACOM LTSAs reduce concentration risk in one sense: they lock in a multi-billion-dollar customer with contractual volume commitments. They increase concentration risk in another sense: MACOM becomes a larger share of revenue. The net effect is positive because the contractual commitment replaces spot-market uncertainty.
The Lumentum extension, the Quintessent partnership, the defense IR purchase orders, and the MACOM LTSAs together represent four distinct revenue streams with four distinct end-market drivers. That is better diversification than IQE had in FY2023 when wireless dominated the mix.
Chart 8: IQE customer qualification status. Lumentum and MACOM are the two confirmed large-tier customers with multi-year agreements. Quintessent is the highest-growth emerging relationship. Raytheon anchors the defense segment. Source: IQE RNS, Shawarma Capital model.
Insider Activity, IP Acquisitions, and What Management Is Signaling
The PDMR filing record through 2025-2026 is dominated by option grants and CLN participation, not market disposals. Mark Cubitt, Executive Chair, participated in the March 2025 CLN financing alongside Bami Bastani. That is a director putting personal capital into the company at a moment of stress. The subsequent option grants to both Cubitt and Jutta Meier, with 3-year holding periods, align management compensation with the recovery thesis.
The Simply Wall St report of an insider share sale in proximity to the fundraising announcement is a governance question worth noting. The timing relative to the capital raise and liquidity disclosures warrants scrutiny. However, the dominant pattern in the PDMR record is option grants and CLN participation, not selling. The net signal is modestly positive.
The Luxtaltek IP acquisition is a separate signal. IQE purchased IP from Luxtaltek's portfolio covering VCSEL and Micro LED epitaxial processes. Luxtaltek is a Taiwanese compound-semiconductor company. The IP covers both VCSEL and Micro LED epiwafer processes. Micro LED is the display technology that Apple, Samsung, and others are developing for next-generation AR/VR headsets and smartwatches. IQE acquiring Luxtaltek IP in VCSEL and Micro LED positions it for the Micro LED display supply chain, which is a multi-year ramp that has not yet materialized at volume but is coming. The IP acquisition is a small investment with a large optionality payoff if Micro LED displays reach mass production.
Position Sizing, Entry Logic, and Where I Add or Trim
IQEPF is 35.1% of the portfolio. That is a concentrated position. It reflects a high-conviction entry near cycle lows at under 1x revenue, reclassified off the avoid list on April 18, 2026. The position has run approximately 179% from the entry mark to the April 20, 2026 print of $0.74. The current price is $0.60 as of May 5, 2026, a pullback from the post-MACOM announcement high.
The pullback is the opportunity. The MACOM deal was announced April 26, 2026. The stock ran 25-30% on the announcement. A sell-side analyst downgraded citing valuation having run ahead of fundamentals. The stock has given back some of that move. The fundamentals have not changed. The MACOM LTSAs are signed. The General Meeting is May 15, 2026. The balance sheet repair is in process.
The add trigger is the May 15, 2026 General Meeting approval. If the retail tranche is approved and the £81M raise completes, the balance sheet repair is confirmed and the MACOM relationship is fully activated. That is the first add trigger.
The second add trigger is the FY2025 full-year results, expected in the May 2026 timeframe. If the results confirm the January 2026 trading update (revenue approximately £97M, EBITDA at least £2M), and if the Q1 2026 order book commentary is positive, that is the second add trigger.
The trim trigger is a re-rate to the base case implied price of $1.25 without a corresponding improvement in the fundamental outlook. If the stock reaches $1.25 on narrative momentum without the photonics revenue build materializing in reported results, that is a trim signal. The position size at 35.1% of the portfolio is already large. A trim at $1.25 to reduce to 25% of the portfolio is the disciplined move.
The exit trigger is a fundamental breakdown: gross margins failing to recover above 5% by FY2027, or the MACOM LTSAs being terminated, or a covenant breach that the MACOM deal fails to prevent. None of those are the current trajectory. The exit is not imminent.
Chart 9: Position sizing trigger framework. The add triggers are event-driven, not price-driven. The trim triggers are valuation-driven. The exit trigger is fundamental. Source: Shawarma Capital model.
What are the catalysts through 2027?
The next 18 months have a dense catalyst schedule. Each event is a probability-weighted re-rate opportunity.
May 15, 2026. General Meeting to approve the £40.8M retail and institutional fundraising tranche at 19.8 pence per share. Approval is the base case. Failure would be a significant negative surprise. Probability of approval: 90%.
May 2026. FY2025 full-year results. Expected to confirm the January 2026 trading update: revenue approximately £97M, adjusted EBITDA at least £2M. Q1 2026 order book commentary is the key forward signal. Probability of positive surprise: 60%.
H2 2026. MACOM LTSA volume ramp. The first full half-year of MACOM supply agreement volumes will appear in H1 2026 results. The photonics revenue line should show the MACOM contribution. Probability of visible MACOM contribution: 70%.
H2 2026. Quintessent CPO purchase order expansion. The initial $0.5M purchase order from January 2025 was for 2025 production deliveries. A follow-on order for 2026-2027 deliveries would confirm the CPO ramp is on track. Probability of follow-on order announcement: 55%.
FY2026 results (May 2027). The first full-year results showing the MACOM LTSA contribution, the photonics mix shift, and the gross margin recovery. If revenue reaches £115M and gross margins turn positive, the multiple re-rate begins in earnest. Probability of £115M+ revenue in FY2026: 55%.
2027. Defense GaN program awards. The UK government-funded GaN programs and the US defense funding releases create a pipeline of potential program awards. A named defense GaN contract would add a new revenue line and a new narrative. Probability of a named defense GaN award by end of 2027: 40%.
2027. Potential US listing or dual listing. Not a confirmed catalyst. A US listing would close the AIM discount and expand the investor base. Probability of a US listing announcement by end of 2027: 15%.
Chart 10: IQE catalyst calendar through 2027. The May 15, 2026 General Meeting is the first gate. The FY2025 results are the second. The H1 2026 results with MACOM LTSA contribution are the first evidence of the strategic partnership translating into revenue. Source: Shawarma Capital model.
The M&A Frame: Why IQE Is a Strategic Asset in the China-Restriction Era
The formal sale process is over. MACOM's investment ended it. But the M&A optionality has not disappeared. It has been restructured.
MACOM now holds 11.5% of IQE's enlarged share count, two board seats, and multi-year supply agreements. That is the first step in a longer process that could end in a full acquisition. MACOM's own EV/Sales multiple of approximately 9.6x implies that a full acquisition of IQE at 8-10x EV/Sales on £200M+ revenue would be accretive to MACOM's revenue base and would eliminate the supply-chain risk that motivated the initial investment.
The alternative acquirers are US defense primes and European semiconductor groups. Raytheon has a 15-year relationship with IQE's North Carolina facility. L3Harris operates in the same defense IR and radar space. Infineon is collaborating with Nvidia on 800V HVDC architecture and needs GaN epiwafer supply. STMicroelectronics has a compound-semiconductor roadmap. Any of these companies could justify an acquisition of IQE on strategic grounds.
The UK government's compound-semiconductor industrial policy makes a forced sale to a non-Western buyer politically impossible. The Bristol and Wales manufacturing cluster is explicitly cited in UK semiconductor strategy. A Chinese acquisition of IQE would face the same regulatory barriers as a Chinese acquisition of any UK defense-adjacent technology company. The Western-only acquirer set is the relevant universe.
The Wolfspeed Chapter 11 precedent is instructive. Wolfspeed emerged from Chapter 11 in September 2025 with $4.6B of debt eliminated and Renesas as an anchor partner. The compound-semiconductor supply chain is being restructured around Western strategic partnerships. IQE's MACOM deal is the same pattern at a smaller scale. The direction of travel is toward consolidation and strategic alignment, not commoditization.
Is $IQEPF a buy? The bottom line
The MACOM deal changed the risk profile of this investment. It did not change the thesis. The thesis was always that IQE is the world's largest compound-semiconductor epiwafer foundry, mispriced at under 1x revenue, sitting at the center of the AI photonics, defense, and 5G supply chains. The MACOM deal confirms that thesis from the outside. A company that trades at 9.6x EV/Sales on its own revenue just paid £45M to lock in IQE's output and took two board seats.
The probability-weighted expected value at the updated scenario weights is $2.90 against a current price of $0.60. The base-case 3-year IRR is approximately 28% annualized. The bull-case 3-year IRR is approximately 76% annualized. The asymmetric bull 4-year IRR is approximately 75% annualized.
The next gate is May 15, 2026. The General Meeting approves the retail tranche. The £81M raise completes. The MACOM LTSAs activate. The balance sheet repair is confirmed. After that, the FY2025 full-year results provide the first look at the Q1 2026 order book in detail.
The market is still pricing IQE as a distressed industrial recovering from a cycle trough. It is something else entirely. It is the Western compound-semiconductor epiwafer foundry that MACOM, Lumentum, Quintessent, and Raytheon cannot operate without. The probability mass has moved. Position accordingly.
Disclosure: I am long IQEPF. This is research synthesis, not investment advice. You should not buy or sell securities based on anything I write. I am not a registered investment advisor. I do not owe you a fiduciary duty. My conclusions could be wrong in ways I have not anticipated. Financial projections are model outputs based on publicly available data. They are not guarantees. Do your own due diligence.
More in this series
The Epiwafer Monopoly: The Complete Series